Brief: Vaccitech Announces HBV Infection Treatment Interim Data

Barinthus Biotherapeutics

12/11/2021 14:21

Nov 12 (Reuters) - Vaccitech PLC  VACC.O :
    * VACCITECH’S VTP-300 WAS WELL-TOLERATED AND INDUCED T CELLS
AGAINST ALL TARGETED HBV ANTIGENS IN BOTH HEALTHY VOLUNTEERS AND
PATIENTS WITH CHRONIC HBV INFECTION IN INTERIM ANALYSES
    * VACCITECH PLC - CHADOX-1-HBV ALONE (HBV001) WAS WELL
TOLERATED
IN HEALTHY VOLUNTEERS AND CHB PATIENTS
    * VACCITECH PLC - VTP-300 (HBV002) WAS WELL-TOLERATED IN CHB
PATIENTS

Source text for Eikon:  ID:nGNX2K7Yw9 
Further company coverage:  VACC.O 

 ((Reuters.Briefs@thomsonreuters.com;))